RLFTY (MindMaze Therapeutics Holding) Preferred Dividends: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RLFTY MindMaze Therapeutics Holding SA RLFTY
11 GF Score
Price $0.42
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Preferred Dividends?

MindMaze Therapeutics Holding RLFTY 11 Preferred Dividends is $0.00 Mil as of Dec. 2025. GuruFocus rates RLFTY with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. MindMaze Therapeutics Holding's preferred dividends for the six months ended in Dec. 2025 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

MindMaze Therapeutics Holding  (OTCPK:RLFTY) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Preferred Dividends Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Preferred Dividends Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Preferred Dividends
0.00 0.00

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Preferred Dividends 0.00 0.00
RLFTY
11GF Score
MindMaze Therapeutics Holding SA RLFTY
Preferred Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of $0.00 Mil mean?
MindMaze Therapeutics Holding (RLFTY) has a Preferred Dividends of $0.00 Mil as of Dec. 2025. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Preferred Dividends too high?
MindMaze Therapeutics Holding's current Preferred Dividends is $0.00 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Preferred Dividends compare to VRTX and REGN?
MindMaze Therapeutics Holding's Preferred Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Preferred Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (RLFTY) has a current Preferred Dividends of $0.00 Mil. The current Preferred Dividends is $0.00 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For MindMaze Therapeutics Holding (RLFTY), the current Preferred Dividends is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges MMTXz:UKMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
11GF Score

Get the complete analysis for RLFTY

Preferred Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price